| Name | Title | Contact Details |
|---|
ARTIO MEDICAL, formerly known as Metactive Medical, is developing innovative endovascular medical devices with the potential to provide immediate and lasting occlusion of aneurysms, blood vessels, and other vascular structures. Artio`s products enable precision placement and provide immediate, complete, and lasting occlusion of target vessel segments and saccular aneurysms. These products will enable physicians to perform better, faster, and safer vascular occlusion procedures.
Ophthonix is a Vista, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardone Record Services is a Tolland, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.
MedShift, founded in 2015 in Charlotte, NC delivers platform as a service to both medical device manufacturers as well as individual medical practices. Foundationally MedShift enables access to the latest devices and technology to remain competitive and attract new business. MedShift has partnered with over 250 providers in North America, Australia, and New Zealand to give practices the latest in cutting-edge treatment modalities, services, and systems. MedShift is disrupting the traditional aesthetic device market by offering permanent placement, holistic subscription services for surgeons, physicians and their business. MedShift`s broad portfolio of services for practices includes a portfolio of 24 leading aesthetic medical devices from six manufacturers, an aesthetic eCommerce and subscription platform, in-house communications and marketing services, and inbound lead generation. For manufacturers MedShift delivers a highly secure IoT platform consisting of both hardware and software assets allowing for real time visibility, remote management, and big data modeling of entire medical device lineups. MedShift adds value across manufacturer and provider spectrum and continues to empower robust integration with leading brands and doctors in the industry.